Global Ganja Report

The claim that cannabis causes "mental illness" rears its dubious head like clockwork every few years, and this latest round has occasioned a virtual media frenzy—a seeming backlash to the recent advances in normalization of the herb and its aficionados. Scratching the claims, however, reveals more hype than rigor.

The headlines are all too familiar ones, but this time they got very prominent play.

In Episode 24 of the CounterVortex podcast, Bill Weinberg notes the historic strides toward liberation of the cannabis plant in 2018, from the fabled four corners of the Earth. Yet under capitalism, every advance also opens new contradictions.

With passage of the Farm Bill and removal of hemp-derived CBD from controlled substance status, big market growth is expected for the very chic and purportedly salubrious non-psychoactive cannabinoid. The law is a win for a nascent CBD industry that has been struggling to shake off the lingering stigma surrounding (psychoactive) cannabis. The effort to segment cannabidiol from "marijuana" is exemplified in the several states that now have "CBD-only" laws.

2018 saw historic strides toward the liberation of the cannabis plant, from the proverbial four corners of the Earth—North America to the Antipodes. Canadian legalization garnered big headlines, but there were significant breaks with the global prohibition regime in several other countries—including some seemingly unlikely candidates, in regions where the anti-cannabis stigma is deeply entrenched.

It has long been established that cannabis can effectively treat glaucoma, a condition that damages the optic nerve and can lead to blindness. However, new research indicates that while THC helps fight glaucoma, its cousin cannabinoid CBD has the opposite effect—and could actually counteract the efficacy of THC.

When the United Kingdom announced the historic step of rescheduling cannabis and allowing physicians to prescribe it two months ago, there was concern from patients and advocates as to whether actual herbaceous flower would be allowed, or only extracts. Now the first patient is approved to receive cannabis under the program, and it is indeed to be dried flower. The bad news: with the National Health Service barred by bureaucratic hurdles from providing it, patients are at the mercy of the market—and the price is prohibitive. 

Terpenes, the chemical compounds that give your herb its distinctive smell and flavor, are increasingly recognized as a vital part of the overall cannabis experience. But with the growing popularity of vape pens and concentrates, industry is now adding terpenes to products in an effort to recreate that whole-flower feel. These may come from plants other than cannabis—and some may even be synthetic.

Days after legalizing medical marijuana, New Zealand's government has confirmed that a referendum on general cannabis legalization will be held in 2020. With the Green Party aggressively pushing the idea, prospects seem good for Aotearoa to follow Uruguay and Canada as the world's third country to legalize.